Mer­ck-part­nered biotech hands Roche its half-life ex­ten­sion tech as it piv­ots to im­muno-on­col­o­gy

It seems few can re­sist the rev­enue that can await a can­cer treat­ment.

Af­ter over a decade ex­tend­ing the half-life of med­i­cines for J&J, Genen­tech and oth­er large play­ers, Amu­nix is piv­ot­ing to de­vel­op el­e­ments of its plat­form in­to two ap­proach­es to im­muno-on­col­o­gy, one of which is an off-the-shelf al­ter­na­tive to CAR–T treat­ments. And they’re li­cens­ing a por­tion of the old­er tech­nol­o­gy to Roche for $40 mil­lion and $1.5 bil­lion in po­ten­tial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER